REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Clinical trials for REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) trials appear
Sign up with your email to follow new studies for REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for stubborn lymphoma: drug duo aims to wipe out tumors
Disease control OngoingThis study tests a combination of the drug glofitamab with chemotherapy (GemOx) in 40 adults with a type of lymphoma that did not respond to initial treatment. The main goal is to see how many patients have their tumors completely disappear for at least 4 weeks. Participants must…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated May 26, 2026 10:27 UTC
-
Can stem cell dose boost recovery in tough lymphoma?
Disease control OngoingThis study looks at whether the number of stem cells given during a transplant affects recovery for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). About 59 adults who have already tried one chemotherapy and are eligible for a stem cell transplant will r…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:50 UTC